Johnson & Johnson (JNJ HM) stock market data APIs
€164.0202
-0.19(-0.1%)
as of October 17, 2025
Try our APIs with
free plan!
Johnson & Johnson Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for JNJ.HM.
Prev. Close
164.0202
Open
163.8312
High
164.0202
Low
163.8312
52 wk Range
127.2046-165.52
Market Cap
385 769 M
Dividends (Yield)
0.0224
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Johnson & Johnson data using free add-ons & libraries
Get Johnson & Johnson Fundamental Data
Johnson & Johnson Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-14
- EPS/Forecast: 2.76
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Johnson & Johnson News
New
S&P 500 Posts Weekly Gain on Tariff Optimism, Better-Than-Expected Earnings
The Standard & Poor's 500 index rose 1.7% this week as earnings season kicked off on a largely posit PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Should You Buy, Sell or Hold J&J Stock After Robust Q3 Earnings?
Johnson & Johnson JNJ delivered strong third-quarter 2025 results, with both the top and bottom lines exceeding expectations. Total revenues rose 6.8% to $24 billion, while adjusted EPS of $2.77 per s...
Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors
BOSTON, October 17, 2025--(BUSINESS WIRE)--Diorasis Therapeutics, a Boston-based biotechnology company developing durable gene therapies for glaucoma and other ophthalmic diseases, today announced the...
J&J Myeloma Combo Hits Late-Stage Goal
This article first appeared on GuruFocus. Johnson & Johnson (NYSE:JNJ) says its Tecvayli paired with Darzalex Faspro hit the main goal in a late-stage study for patients with relapsed or refractory m...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
